BioSpace News Archive

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23.

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company’s ETX0462 candidate in the prestigious scientific journal Nature (DOI: 10.1038/s41586-021-03899-0).

aTyr Pharma, Inc., a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it has commenced an underwritten public offering of shares of its common stock.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Tuesday, September 21, 2021, at 9:55 a.m. ET.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted a new analysis suggesting that the Moderna COVID-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the U.S. Centers for Disease Control and Prevention (CDC)

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT.

Protagonist Therapeutics, Inc. reported that on September 15, 2021, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY

Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology Congress, which will be hosted virtually September 16-21, 2021.

BioCryst Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute for Health and Care Excellence has recommended ORLADEYO® for preventing recurrent attacks of hereditary angioedema in eligible patients 12 years and older if they have at least two attacks per month.